141 related articles for article (PubMed ID: 34979067)
21. The prognostic value of spirometric tests in Amyotrophic Lateral Sclerosis patients.
Pirola A; De Mattia E; Lizio A; Sannicolò G; Carraro E; Rao F; Sansone V; Lunetta C
Clin Neurol Neurosurg; 2019 Sep; 184():105456. PubMed ID: 31382080
[TBL] [Abstract][Full Text] [Related]
22. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis.
Oh KW; Noh MY; Kwon MS; Kim HY; Oh SI; Park J; Kim HJ; Ki CS; Kim SH
Ann Neurol; 2018 Sep; 84(3):361-373. PubMed ID: 30048006
[TBL] [Abstract][Full Text] [Related]
23. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
[TBL] [Abstract][Full Text] [Related]
24. Plasma exchange with albumin replacement and disease progression in amyotrophic lateral sclerosis: a pilot study.
Povedano M; Paipa A; Barceló M; Woodward MK; Ortega S; Domínguez R; Aragonés ME; Horrillo R; Costa M; Páez A
Neurol Sci; 2022 May; 43(5):3211-3221. PubMed ID: 34791571
[TBL] [Abstract][Full Text] [Related]
25. Relative effects of forced vital capacity and ALSFRS-R on survival in ALS.
Daghlas SA; Govindarajan R;
Muscle Nerve; 2021 Sep; 64(3):346-351. PubMed ID: 34076262
[TBL] [Abstract][Full Text] [Related]
26. Functional and Endoscopic Indicators for Percutaneous Endoscopic Gastrostomy (PEG) in Amyotrophic Lateral Sclerosis Patients.
Conde B; Martins N; Rodrigues I; Pimenta AC; Winck JC
J Clin Med; 2018 Oct; 7(10):. PubMed ID: 30322191
[TBL] [Abstract][Full Text] [Related]
27. [Revised amyotrophic lateral sclerosis functional rating scale at time of diagnosis predicts survival time in amyotrophic lateral sclerosis].
Liu XX; Fan DS; Zhang J; Zhang S; Zheng JY
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(35):2472-5. PubMed ID: 20137433
[TBL] [Abstract][Full Text] [Related]
28. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
29. Intravenous transplantation of bone marrow-derived mesenchymal stromal cells in patients with multiple sclerosis, a phase I/IIa, double blind, randomized controlled study.
Nabavi SM; Karimi S; Arab L; Aghdami N; Joghtaei N; Maroufizadeh S; Jarooghi N; Bolurieh T; Abbasi F; Mardpour S; Azimyian V; Moeininia F; Sanjari L; Hosseini SE; Vosough M
Mult Scler Relat Disord; 2023 Oct; 78():104895. PubMed ID: 37515913
[TBL] [Abstract][Full Text] [Related]
30. Correlation between Forced Vital Capacity and Slow Vital Capacity for the assessment of respiratory involvement in Amyotrophic Lateral Sclerosis: a prospective study.
Pinto S; de Carvalho M
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Feb; 18(1-2):86-91. PubMed ID: 27915482
[TBL] [Abstract][Full Text] [Related]
31. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
Imamura K; Izumi Y; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Egawa N; Ayaki T; Oki R; Fujita K; Uozumi R; Morinaga A; Hirohashi T; Fujii Y; Yamamoto T; Tatebe H; Tokuda T; Takahashi N; Morita S; Takahashi R; Inoue H
EClinicalMedicine; 2022 Nov; 53():101707. PubMed ID: 36467452
[TBL] [Abstract][Full Text] [Related]
33. Cellular transplants in amyotrophic lateral sclerosis patients: an observational study.
Gamez J; Carmona F; Raguer N; Ferrer-Sancho J; Martín-Henao GA; Martí-Beltrán S; Badia M; Gratacós M; Rodriguez-Gónzalez E; Seoane JL; Pallero-Castillo M; Burgos R; Puiggros C; Pasarin A; Bori-Fortuny I
Cytotherapy; 2010 Sep; 12(5):669-77. PubMed ID: 20586670
[TBL] [Abstract][Full Text] [Related]
34. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2012 Dec; 12():CD005225. PubMed ID: 23235621
[TBL] [Abstract][Full Text] [Related]
35. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920
[TBL] [Abstract][Full Text] [Related]
36. Comparison of slow and forced vital capacities on ability to predict survival in ALS.
Pinto S; de Carvalho M
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Nov; 18(7-8):528-533. PubMed ID: 28741375
[TBL] [Abstract][Full Text] [Related]
37. A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis.
Logan A; Nagy Z; Barnes NM; Belli A; Di Pietro V; Tavazzi B; Lazzarino G; Lazzarino G; Bruce L; Persson LI
PLoS One; 2022; 17(5):e0267183. PubMed ID: 35613082
[TBL] [Abstract][Full Text] [Related]
38. Low 25OH Vitamin D Blood Levels Are Independently Associated With Higher Amyotrophic Lateral Sclerosis Severity Scores: Results From a Prospective Study.
Juntas-Morales R; Pageot N; Marin G; Dupuy AM; Alphandery S; Labar L; Esselin F; Picot MC; Camu W
Front Neurol; 2020; 11():363. PubMed ID: 32547467
[No Abstract] [Full Text] [Related]
39. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results.
Berry JD; Cudkowicz ME; Windebank AJ; Staff NP; Owegi M; Nicholson K; McKenna-Yasek D; Levy YS; Abramov N; Kaspi H; Mehra M; Aricha R; Gothelf Y; Brown RH
Neurology; 2019 Dec; 93(24):e2294-e2305. PubMed ID: 31740545
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility.
Kim HY; Moon C; Kim KS; Oh KW; Oh SI; Kim J; Kim SH
J Clin Neurol; 2014 Oct; 10(4):342-7. PubMed ID: 25324884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
